G1 Therapeutics, Inc. (GTHX)
| Market Cap | 728.31M |
| Revenue (ttm) | 57.36M |
| Net Income (ttm) | -94.67M |
| Shares Out | 40.70M |
| EPS (ttm) | -2.45 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 30 |
| Last Price | $17.31 |
| Previous Close | $17.38 |
| Change ($) | -0.07 |
| Change (%) | -0.40% |
| Day's Open | 17.18 |
| Day's Range | 16.98 - 17.44 |
| Day's Volume | 568,461 |
| 52-Week Range | 10.81 - 37.07 |
RESEARCH TRIANGLE PARK, N.C., July 19, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the U.S. Food and Drug Administration (FDA...
RESEARCH TRIANGLE PARK, N.C., July 02, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisab...
RESEARCH TRIANGLE PARK, N.C., June 18, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the appointment of Alicia Secor to its Board of...
RESEARCH TRIANGLE PARK, N.C., June 16, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that G1's Chief Executive Officer Jack Bailey w...
G1 Therapeutics Inc (NASDAQ: GTHX) has initiated the PRESERVE 3 Phase 2 study evaluating Cosela (trilaciclib) in patients with untreated, locally advanced, or metastatic urothelial carcinoma (mUC). Cose...
RESEARCH TRIANGLE PARK, N.C., June 04, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisab...
- Combination of Rintodestrant and Palbociclib was Very Well Tolerated with No Reported Discontinuations due to Treatment-Emergent Adverse Events (TEAEs) -
RESEARCH TRIANGLE PARK, N.C., June 04, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a commercial-stage oncology company, today presented results from analyses evaluating the immune e...
RESEARCH TRIANGLE PARK, N.C., May 19, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced upcoming data presentations at the American Soci...
- A Cost-Benefit Model of Administration of COSELATM (trilaciclib) Prior to Chemotherapy Estimates Measurable Per-Patient Cost Savings -
PRESERVE 4 Will Evaluate the Survival and Myeloprotection Benefits of COSELA in 146 Patients with Non-Small Cell Lung Cancer (NSCLC) Previously Treated with Checkpoint Inhibitors PRESERVE 4 Will Evaluat...
G1 THERAPEUTICS (GTHX) delivered earnings and revenue surprises of 40.37% and 3711.80%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
- G1's COSELA™ (trilaciclib), the Only FDA-Approved Proactive Multilineage Myeloprotection Therapy, Approved on February 12, 2021 and Commercially Available as of March 2, 2021 -
RESEARCH TRIANGLE PARK, N.C., April 28, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a corporate...
- Pivotal Program Evaluated the Effects of Administering COSELA Prior to Chemotherapy on Clinically Relevant Endpoints Across Multiple Hematopoietic Lineages, Including Hematologic Adverse Events, Labor...
RESEARCH TRIANGLE PARK, N.C., April 07, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that G1's Chief Executive Officer Jack Bailey ...
RESEARCH TRIANGLE PARK, N.C., April 01, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the Company will host a virtual COSELA Ki...
COSELA Added to Both the NCCN Treatment Guidelines for Small Cell Lung Cancer and the NCCN Supportive Care Guidelines for Hematopoietic Growth Factors COSELA Added to Both the NCCN Treatment Guidelines ...
RESEARCH TRIANGLE PARK, N.C., March 03, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the Company will participate in two inves...
- Launch of Innovative Therapy for People Living with Extensive-Stage Small Cell Lung Cancer is Supported by the G1 to One™ Patient Support Program, the Single Source for COSELA Access Solutions - - Lau...
Shares of G1 Therapeutics (NASDAQ:GTHX) rose in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 28.72% year over year to ($0.67), which beat the est...
- G1's COSELA™ (trilaciclib) Approved by FDA as First and Only Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression; Commercial Availability Expected in Early March -
RESEARCH TRIANGLE PARK, N.C., Feb. 17, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a corporate ...
G1 Therapeutics Inc (NASDAQ: GTHX) shares gain premarket after FDA approves COSELA (trilaciclib) for injection to decrease the incidence of chemotherapy-induced myelosuppression (damage to bone marrow) ...
- COSELA is the only FDA-approved therapy that helps proactively deliver multilineage myeloprotection to patients with extensive-stage small cell lung cancer being treated with chemotherapy -
RESEARCH TRIANGLE PARK, N.C., Feb. 04, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that G1's Chief Executive Officer Jack Bailey wil...
NEW YORK--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces its investigation of G1 Therapeutics, Inc. (Nasdaq: GTHX) concerning the Company and its directors' and officers' possible violat...
G1 Therapeutics has a PDUFA date coming up on February 15, 2021 for its first therapy, trilaciclib in SCLC. G1's stock has moved hugely upward over the last few months as investors begin to anticipate t...
RESEARCH TRIANGLE PARK, N.C., Jan. 05, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Jack Bailey will pre...
- Company also reports inducement grant under Nasdaq Listing Rule 5635(c)(4) -
Company also presents updated monotherapy data on investigational oral selective estrogen receptor degrader (SERD) rintodestrant for ER+, HER2- breast cancer Company also presents updated monotherapy da...
GTHX stock is depressed but I don't see any reason. PDUFA of Feb. 15, 2021, is a major catalyst.
RESEARCH TRIANGLE PARK, N.C., Nov. 24, 2020 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that incoming Chief Executive Officer Jack Bailey...
Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider buying can ...
RESEARCH TRIANGLE PARK, N.C., Nov. 18, 2020 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that final overall survival (OS) data from its ra...
RESEARCH TRIANGLE PARK, N.C., Nov. 11, 2020 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Jack Bailey will pre...
G1 Therapeutics, Inc. (GTHX) CEO Mark Velleca on Q3 2020 Results - Earnings Call Transcript
RESEARCH TRIANGLE PARK, N.C., Oct. 28, 2020 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that it will host a webcast and conference call t...
RESEARCH TRIANGLE PARK, N.C., Oct. 15, 2020 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that four presentations highlighting the myelopre...
- Mark Velleca, M.D., Ph.D., G1’s first Chief Executive Officer, to serve as senior advisor and remain member of the G1 Board of Directors
RESEARCH TRIANGLE PARK, N.C., Sept. 14, 2020 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a clinical-stage oncology company, today announced that two presentations highlighting data on ...
RESEARCH TRIANGLE PARK, N.C., Sept. 02, 2020 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a clinical-stage oncology company, today announced that the company will participate in the fol...
Oncology Stocks Area Trading Materially Lower The Last 2 Months
Of a pool of 26 oncology stocks we track, with 1 exception, all (literally 25 of 26) are trading materially lower from the third week of June 2020.
- PDUFA action date of February 15, 2021 assigned by U.S. Food and Drug Administration - Priority Review for trilaciclib is based on positive data from three randomized clinical trials showing robust m...
G1 Therapeutics' (GTHX) CEO Mark Velleca on Q2 2020 Results - Earnings Call Transcript
- Submitted New Drug Application (NDA) for trilaciclib in small cell lung cancer (SCLC) - Co-promotion agreement with Boehringer Ingelheim for U.S. trilaciclib launch - Partnership for trilaciclib in ...
RESEARCH TRIANGLE PARK, N.C., Aug. 04, 2020 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a clinical-stage oncology company, today announced that Chief Executive Officer Mark Velleca, M....
RESEARCH TRIANGLE PARK, N.C., July 29, 2020 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a clinical-stage oncology company, today announced that it will host a webcast and conference ca...
- G1 to receive $20 million upfront payment, sales royalties and potential milestone payments of up to $290 million for commercialization of lerociclib in the U.S., Europe, Japan
About GTHX
G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor tha... [Read more...]
| Industry Biotechnology | IPO Date May 17, 2017 |
| CEO Mark Velleca | Employees 122 |
| Stock Exchange NASDAQ | Ticker Symbol GTHX |
Analyst Forecasts
According to 8 analysts, the average rating for GTHX stock is "Buy." The 12-month stock price forecast is 59.00, which is an increase of 240.84% from the latest price.